|Mr. Andrea Recordati||CEO & Director||N/A||N/A||1971|
|Mr. Fritz Squindo||CFO, MD & Exec. Director||N/A||N/A||1956|
|Ms. Marianne Tatschke||Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Daria Ghidoni||VP of Corp. Legal Counsel||N/A||N/A||N/A|
|Mr. Gabriele Finzi||VP of Corp. Devel. & Licensing||N/A||N/A||N/A|
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals in Europe, the Middle East, Africa, the United States, Canada, and internationally. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, gynecology and obstetrics, medical devices, musculo-skeletal disorders and analgesia, over the counter/non-prescription pharmaceuticals, urology, allergy, anti-infectives, central nervous system, endocrinology, gastrointestinal, nutrition and related products, immune-suppressants, pain management/inflammation, generics, pneumology, antipyretics and cold preparations, endocrinology, oncology, respiratory, and radio contrast agent, as well as ear, nose, and throat. It also provides pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy.
Recordati Industria Chimica e Farmaceutica S.p.A.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 1; Compensation: 9.